Advantage Alpha Capital Partners LP Entrada Therapeutics, Inc. Transaction History

Advantage Alpha Capital Partners LP

  • $419 Million
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
SELL
$11.85 - $16.45 $1.08 Million - $1.5 Million
-91,096 Reduced 99.98%
20 $0
Q1 2024

May 13, 2024
SELL
$11.58 - $17.0 $162,363 - $238,357
-14,021 Reduced 13.34%
91,116 $1.29 Million
Q4 2023

Feb 13, 2024
BUY
$11.36 - $16.99 $1.19 Million - $1.79 Million
105,137 New
105,137 $1.59 Million

Others Institutions Holding TRDA

# of Institutions
101
Shares Held
28.1M
Call Options Held
34.5K
Put Options Held
16.4K
View Full List

About Entrada Therapeutics, Inc.

TRDA Quotes by TradingView
  • Ticker TRDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,368,500
  • Market Cap $551M
  • Description
  • Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...
More about TRDA
Track This Portfolio

Track Advantage Alpha Capital Partners LP Portfolio

Follow Advantage Alpha Capital Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advantage Alpha Capital Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Advantage Alpha Capital Partners LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email